NYSE - Delayed Quote
USD
Teva Pharmaceutical Industries Limited (TEVA)
42.61
+0.83
(+1.99%)
At close: November 6 at 4:00:02 PM EST
42.75
+0.14
(+0.33%)
After hours: 8:00:00 PM EST
Trade TEVA on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreAnalyst Insights
Top Analyst
B of A Securities
54/100
Analyst Price Targets
Analyst Recommendations
-
Strong Buy
-
Buy
-
Hold
-
Underperform
-
Sell
Latest Rating
Date
11/5/2026
Analyst
Leerink Partners
Rating Action
Maintains
Rating
Outperform
Price Action
Raises
Price Target
45 -> 52
Top Analysts
Yahoo Finance’s Top Analysts section provides an objective scorecard to evaluate the accuracy of Wall Street analyst ratings and price targets.
Learn more
Yahoo Finance’s Top Analysts section provides an objective scorecard to evaluate the accuracy of Wall Street analyst ratings and price targets.
Learn more| Analyst
|
Overall Score
|
Direction Score
|
Price Score
|
Latest Rating
|
Price Target
|
Date
|
|---|---|---|---|---|---|---|
|
B of A Securities
|
54 | 51 | 80 | Buy
|
42 | 2026-04-09 |
|
Jefferies
|
54 | 51 | 82 | Buy
|
40 | 2026-01-06 |
|
Piper Sandler
|
51 | 35 | 87 | Overweight
|
44 | 2026-07-28 |
|
UBS
|
50 | 40 | 89 | Buy
|
48 | 2026-09-04 |
|
Barclays
|
47 | 35 | 96 | Overweight
|
47 | 2026-10-15 |
|
Goldman Sachs
|
46 | 34 | 82 | Buy
|
45 | 2026-02-09 |
|
JP Morgan
|
43 | 33 | 69 | Overweight
|
50 | 2026-10-12 |
|
Oppenheimer
|
24 | 17 | 30 | Outperform
|
50 | 2026-09-24 |
Rows per page
1-8 of 8
Upgrades & Downgrades
| Maintains | Leerink Partners: Outperform to Outperform | 11/5/2026 |
| Maintains | TD Cowen: Buy to Buy | 11/4/2026 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 11/4/2026 |
| Initiated | HC Wainwright & Co.: Buy | 11/2/2026 |
| Maintains | Barclays: Overweight to Overweight | 10/15/2026 |
| Maintains | JP Morgan: Overweight to Overweight | 10/12/2026 |
